New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.60
0.15
+0.09%
Follow AZN
Alert me
Revenue to profit Twelve months to Sep 30, 2026
Of every $100 of revenue, $21.32 was left as profit. Gross margin has risen two quarters running, from 81.7% to 81.9%. What is an income statement?
| Revenue | 62.4 | 100.0% |
|---|---|---|
| Cost of revenue | −11.3 | −18.1% |
| Gross profit | 51.1 | 81.9% |
| Research & development | −15.3 | −24.5% |
| Selling, general & admin | −21.8 | −34.9% |
| Other operating costs | +0.7 | 1.2% |
| Operating income | 14.8 | 23.7% |
| Other income, net | −1.5 | −2.4% |
| Income tax | −2.3 | −3.6% |
| Other items | +2.3 | 3.6% |
| Net income | 13.3 | 21.3% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $58.7B | $60.4B | $61.4B | $62.4B |
| Operating income | $13.7B | $14.3B | $14.0B | $14.8B |
| Net income | $12.4B | $12.9B | $12.6B | $13.3B |
| Net margin (right axis) | 21.1% | 21.4% | 20.5% | 21.3% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
62,384.00 | 61,366.00 | 60,439.00 | 58,739.00 |
+8 more TTM periods Free account |
Cost of Revenue |
11,265.00 | 11,120.00 | 11,070.00 | 10,633.00 | |
Gross Profit |
51,119.00 | 50,246.00 | 49,369.00 | 48,106.00 | |
R&D Expenses |
15,301.00 | 15,070.00 | 14,565.00 | 14,232.00 | |
SG&A Expenses |
21,761.00 | 21,735.00 | 20,946.00 | 20,512.00 | |
Operating Income |
14,775.00 | 13,971.00 | 14,315.00 | 13,743.00 | |
Non-operating Income/Expense |
(1,475.00) | (1,385.00) | (1,401.00) | (1,341.00) | |
Non-operating Interest Expenses |
1,777.00 | 1,734.00 | 1,738.00 | 1,694.00 | |
| 13,300.00 | 12,586.00 | 12,914.00 | 12,402.00 | ||
Income Tax Provision |
2,266.00 | 2,133.00 | 2,521.00 | 2,169.00 | |
Income after Tax |
11,034.00 | 10,453.00 | 10,393.00 | 10,233.00 | |
Non-Controlling Interest |
4.00 | 7.00 | 4.00 | 8.00 | |
Net Income Common |
11,030.00 | 10,446.00 | 10,389.00 | 10,225.00 | |
EPS (Basic) |
7.12 | 6.74 | 6.71 | 6.60 | |
EPS (Diluted) |
7.06 | 6.68 | 6.65 | 6.54 | |
Shares (Basic, Weighted) |
1,550.00 | 1,550.00 | 1,549.75 | 1,550.00 | |
Shares (Diluted, Weighted) |
1,562.00 | 1,562.25 | 1,562.00 | 1,562.00 | |
Gross Margin |
81.94% | 81.88% | 81.68% | 81.90% | |
EBIT Margin |
23.68% | 22.77% | 23.69% | 23.40% | |
EBT margin |
21.32% | 20.51% | 21.37% | 21.11% | |
Net Profit Margin |
17.68% | 17.02% | 17.19% | 17.41% | |
Free Cash Flow Margin |
10.15% | 10.21% | 13.14% | 15.01% | |
EBITDA |
21,186.00 | 20,326.00 | 20,130.00 | 19,476.00 | |
EBIT |
14,775.00 | 13,971.00 | 14,315.00 | 13,743.00 | |
EPS (Diluted, from Cont. Ops) |
3.79 | 3.42 | 3.38 | 3.28 | |
EPS (Diluted, Consolidated) |
3.79 | 3.42 | 3.38 | 3.28 | |
EPS (Basic, Consolidated) |
3.82 | 3.44 | 3.41 | 3.30 | |
Shares (Diluted, Average) |
1,561.00 | 1,561.90 | 1,561.65 | 1,561.65 | |
EPS (Basic, from Continuous Ops) |
3.82 | 3.44 | 3.41 | 3.30 | |
Income from Continuous Operations |
11,034.00 | 10,453.00 | 10,393.00 | 10,233.00 | |
Consolidated Net Income/Loss |
11,034.00 | 10,453.00 | 10,393.00 | 10,233.00 | |
EBITDA Margin |
33.96% | 33.12% | 33.31% | 33.16% | |
Operating Cash Flow Margin |
21.21% | 22.33% | 23.53% | 24.81% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026